KR20250152665A - Ｆc-함유 폴리펩타이드의 안정화 - Google Patents

Ｆc-함유 폴리펩타이드의 안정화

Info

Publication number
KR20250152665A
KR20250152665A KR1020257032842A KR20257032842A KR20250152665A KR 20250152665 A KR20250152665 A KR 20250152665A KR 1020257032842 A KR1020257032842 A KR 1020257032842A KR 20257032842 A KR20257032842 A KR 20257032842A KR 20250152665 A KR20250152665 A KR 20250152665A
Authority
KR
South Korea
Prior art keywords
val
pro
ser
thr
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020257032842A
Other languages
English (en)
Korean (ko)
Inventor
구나세카란 카난
제니퍼 라발리
프레더릭 더블유. 야콥센
Original Assignee
암젠 인크
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 암젠 인크 filed Critical 암젠 인크
Publication of KR20250152665A publication Critical patent/KR20250152665A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
KR1020257032842A 2013-07-31 2014-07-30 Ｆc-함유 폴리펩타이드의 안정화 Pending KR20250152665A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361860800P 2013-07-31 2013-07-31
US61/860,800 2013-07-31
KR1020237032656A KR20230141929A (ko) 2013-07-31 2014-07-30 Ｆc-함유 폴리펩타이드의 안정화
PCT/US2014/048908 WO2015017548A2 (en) 2013-07-31 2014-07-30 Stabilization of fc-containing polypeptides

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020237032656A Division KR20230141929A (ko) 2013-07-31 2014-07-30 Ｆc-함유 폴리펩타이드의 안정화

Publications (1)

Publication Number Publication Date
KR20250152665A true KR20250152665A (ko) 2025-10-23

Family

ID=52432568

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020167004786A Ceased KR20160034404A (ko) 2013-07-31 2014-07-30 Ｆc-함유 폴리펩타이드의 안정화
KR1020237032656A Ceased KR20230141929A (ko) 2013-07-31 2014-07-30 Ｆc-함유 폴리펩타이드의 안정화
KR1020257032842A Pending KR20250152665A (ko) 2013-07-31 2014-07-30 Ｆc-함유 폴리펩타이드의 안정화

Family Applications Before (2)

Application Number Title Priority Date Filing Date
KR1020167004786A Ceased KR20160034404A (ko) 2013-07-31 2014-07-30 Ｆc-함유 폴리펩타이드의 안정화
KR1020237032656A Ceased KR20230141929A (ko) 2013-07-31 2014-07-30 Ｆc-함유 폴리펩타이드의 안정화

Country Status (15)

Country Link
US (3) US20160193295A1 (enExample)
EP (1) EP3027647A4 (enExample)
JP (2) JP2016526909A (enExample)
KR (3) KR20160034404A (enExample)
CN (1) CN105658664A (enExample)
AU (3) AU2014296215A1 (enExample)
BR (1) BR112016002219A2 (enExample)
CA (1) CA2919076C (enExample)
CL (1) CL2016000232A1 (enExample)
EA (1) EA035319B1 (enExample)
HK (1) HK1224203A1 (enExample)
IL (1) IL243690B (enExample)
MX (2) MX2016001165A (enExample)
SG (1) SG11201600734YA (enExample)
WO (1) WO2015017548A2 (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6254146B2 (ja) 2012-03-27 2017-12-27 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド 代謝障害を治療するための組成物および方法
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
RU2704285C2 (ru) 2013-01-30 2019-10-25 Нгм Байофармасьютикалз, Инк. Композиции и способы применения для лечения метаболических расстройств
FR3012453B1 (fr) 2013-10-31 2015-11-13 Lab Francais Du Fractionnement Proteine chimerique dans le traitement de l’amylose
SG10201802098UA (en) 2014-07-30 2018-04-27 Ngm Biopharmaceuticals Inc Compositions and methods of use for treating metabolic disorders
CN115043945A (zh) 2014-10-31 2022-09-13 Ngm生物制药有限公司 用于治疗代谢病症的组合物和方法
US20160175458A1 (en) 2014-12-19 2016-06-23 Alkermes, Inc. Single chain fc fusion proteins
US10259859B2 (en) 2015-08-07 2019-04-16 ALX Oncology Inc. Constructs having a SIRP-α domain or variant thereof
CN109475627B (zh) 2016-05-26 2023-01-06 齐鲁普吉湾生物治疗公司 抗体混合物
JP7084881B2 (ja) * 2016-06-22 2022-06-15 アルカームス インコーポレーテッド Ｉｌ－１０の免疫刺激特性および抗炎症特性を調節するための組成物および方法
JP7250677B2 (ja) * 2016-12-22 2023-04-03 キュー バイオファーマ， インコーポレイテッド Ｔ細胞調節多量体ポリペプチド及びその使用方法
WO2018144784A1 (en) * 2017-02-01 2018-08-09 Smet Pharmaceutical Inc. MONOMERIC HUMAN IgG1 Fc AND BISPECIFIC ANTIBODIES
BR112020000273A2 (pt) * 2017-07-07 2020-07-14 Hanmi Pharm. Co., Ltd. proteína de fusão de enzima e seu método de preparação, composição farmacêutica, polinucleotídeo que codifica a proteína de fusão de enzima, vetor de expressão, transformante
CN111182915A (zh) * 2017-08-15 2020-05-19 金德雷德生物科学股份有限公司 兽药用IgG Fc变体
CN107540748B (zh) * 2017-09-15 2020-07-14 北京伟杰信生物科技有限公司 长效重组猪fsh融合蛋白及其制备方法与应用
EP3708661A4 (en) 2017-12-22 2021-12-01 Hanmi Pharm. Co., Ltd. THERAPEUTIC ENZYMFUSION PROTEIN WITH A NEW STRUCTURE AND ITS USE
TWI724392B (zh) 2018-04-06 2021-04-11 美商美國禮來大藥廠 生長分化因子15促效劑化合物及其使用方法
CN109021109A (zh) * 2018-07-20 2018-12-18 上海交通大学 一种牛源性抗金黄色葡萄球菌融合抗体scFv-Fc及其制备方法
UA129980C2 (uk) 2018-08-03 2025-10-01 Емджен Рісерч (Мюнік) Ґмбг Конструкція на основі антитіл для зв'язування cldn18.2 і cd3
US10947278B2 (en) * 2018-09-19 2021-03-16 Bioapplications Inc. Recombinant vector comprising porcine FC fragment and preparation method of recombinant protein using thereof
KR102200773B1 (ko) * 2018-09-19 2021-01-12 주식회사 바이오앱 돼지의 Fc 단편과 융합된 항원 및 이를 포함하는 백신 조성물
KR102148405B1 (ko) * 2018-09-19 2020-08-27 주식회사 바이오앱 돼지의 Fc 단편을 포함하는 재조합 벡터 및 상기 벡터를 이용한 재조합 단백질의 제조 방법
US20220144916A1 (en) * 2019-02-12 2022-05-12 Board Of Regents, The University Of Texas System High affinity engineered t-cell receptors targeting cmv infected cells
CN119700933A (zh) 2019-05-31 2025-03-28 Alx肿瘤生物技术公司 用SIRPαFc融合体组合免疫检查点抑制剂治疗癌症的方法
US20220227888A1 (en) 2019-06-07 2022-07-21 Amgen Inc. Bispecific binding constructs with selectively cleavable linkers
PE20221416A1 (es) * 2019-09-18 2022-09-20 Novartis Ag Proteinas de fusion nkg2d y sus usos
NZ787541A (en) 2019-11-25 2025-10-31 Alkermes Inc Substituted macrocyclic compounds and related methods of treatment
MY209909A (en) * 2019-12-11 2025-08-11 Lg Chemical Ltd Fusion polypeptide comprising gdf15 and polypeptide region capable of o-glycosylation
EP4093771A1 (en) 2020-01-22 2022-11-30 Amgen Research (Munich) GmbH Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof
JP7481856B2 (ja) * 2020-02-25 2024-05-13 シスメックス株式会社 改変抗体及びその製造方法、並びに抗体の熱安定性を向上させる方法
CN111285936A (zh) * 2020-03-11 2020-06-16 北京双赢科创生物科技有限公司 靶向肿瘤的酸性敏感纳米肽段及其应用
TW202200615A (zh) 2020-03-12 2022-01-01 美商安進公司 用於治療和預防患者的crs之方法
MX2022014636A (es) 2020-05-19 2023-02-23 Amgen Inc Construcciones de unión a mageb2.
CN116096736A (zh) * 2020-08-14 2023-05-09 武汉友微生物技术有限公司 新型冠状病毒rbd融合蛋白
CA3189721A1 (en) * 2020-08-21 2022-02-24 Ajou University Industry-Academic Cooperation Foundation Antibody fragment consisting of heavy chain and light chain constant regions in which gamma constant region (c.gamma.1) and epsilon constant reggion (c.epsilon.2-4) are fused, and use thereof
CN114426974B (zh) * 2020-10-29 2023-11-21 洛阳普泰生物技术有限公司 特异性结合非洲猪瘟病毒CD2v蛋白的抗体或抗体片段
US12161692B2 (en) 2020-11-02 2024-12-10 Attralus, Inc. SAP FC fusion proteins and methods of use
TW202233679A (zh) 2020-11-06 2022-09-01 德商安美基研究（慕尼黑）公司 選擇性地與cldn6和cd3結合的多肽構建體
JP2023552375A (ja) * 2020-12-06 2023-12-15 エーエルエックス オンコロジー インコーポレイテッド 血清学的アッセイにおいてｃｄ４７に結合する薬物の干渉を低減するための多量体
US11760747B2 (en) 2020-12-21 2023-09-19 Alkermes, Inc. Substituted piperidino compounds and related methods of treatment
JP2024520902A (ja) 2021-05-13 2024-05-27 エーエルエックス オンコロジー インコーポレイテッド がんを治療するための併用療法
US20240350588A1 (en) * 2021-08-24 2024-10-24 Sunshine Lake Pharma Co., Ltd. Gdf15 fusion proteins and use thereof
CN116064562A (zh) * 2022-10-28 2023-05-05 江南大学 玉米赤霉烯酮的真核表达单链抗体以及全长抗体的制备方法以及用途
CN119080948B (zh) * 2023-04-17 2025-05-27 北京康乐卫士生物技术股份有限公司 带状疱疹病毒疫苗的嵌合抗原及其应用
WO2025036564A1 (de) * 2023-08-17 2025-02-20 Gottfried Wilhelm Leibniz Universität Hannover (Luh) Nukleinsäuresequenz, vektor, screening-verfahren und verfahren zur herstellung von rekombinanten antikörpern
WO2025162458A1 (zh) * 2024-02-04 2025-08-07 南通壹宸生物医药科技有限公司 融合抗体及其制备和应用
CN118344462B (zh) * 2024-06-18 2024-11-08 苏州易合医药有限公司 一种用于肺部给药的索马鲁肽突变体、融合蛋白及相关产品
CN119613573B (zh) * 2025-02-14 2025-05-30 浙江大学 一种CD40L-Fc融合蛋白、基因片段、重组质粒、重组细胞以及制备方法和用途
CN119735654B (zh) * 2025-02-27 2025-07-01 浙江海隆生物科技股份有限公司 一种牛副流感病毒的亚单位hn蛋白制备方法和应用
CN120623322B (zh) * 2025-08-14 2025-12-05 成都蓉生药业有限责任公司 一种人IgG Fc变体、基因片段、表达载体、宿主细胞、IgG抗体及人IgG Fc变体制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030207346A1 (en) * 1997-05-02 2003-11-06 William R. Arathoon Method for making multispecific antibodies having heteromultimeric and common components
US7951917B1 (en) * 1997-05-02 2011-05-31 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
AU751659B2 (en) * 1997-05-02 2002-08-22 Genentech Inc. A method for making multispecific antibodies having heteromultimeric and common components
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US7754209B2 (en) * 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
AU2005282700A1 (en) * 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
US10155816B2 (en) * 2005-11-28 2018-12-18 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
EP2504360B1 (en) * 2009-11-23 2018-08-15 Amgen Inc. Monomeric antibody fc
CA2819038C (en) * 2010-12-06 2023-10-17 Seattle Genetics, Inc. Humanized antibodies to liv-1 and use of same to treat cancer

Also Published As

Publication number Publication date
WO2015017548A3 (en) 2015-11-05
IL243690A0 (en) 2016-04-21
JP2021019598A (ja) 2021-02-18
AU2020200329A1 (en) 2020-02-06
CA2919076A1 (en) 2015-02-05
US20250325631A1 (en) 2025-10-23
MX2016001165A (es) 2016-06-29
IL243690B (en) 2022-09-01
EA201690299A1 (ru) 2016-11-30
US20160193295A1 (en) 2016-07-07
US20190192628A1 (en) 2019-06-27
AU2014296215A1 (en) 2016-02-11
MX2022008013A (es) 2022-07-27
WO2015017548A2 (en) 2015-02-05
BR112016002219A2 (pt) 2017-09-12
CA2919076C (en) 2024-01-30
KR20230141929A (ko) 2023-10-10
CN105658664A (zh) 2016-06-08
AU2022201204B2 (en) 2025-01-02
EP3027647A4 (en) 2017-01-04
JP2016526909A (ja) 2016-09-08
SG11201600734YA (en) 2016-02-26
CL2016000232A1 (es) 2016-09-02
AU2022201204A1 (en) 2022-03-17
KR20160034404A (ko) 2016-03-29
HK1224203A1 (zh) 2017-08-18
EA035319B1 (ru) 2020-05-27
EP3027647A2 (en) 2016-06-08
JP7344858B2 (ja) 2023-09-14

Similar Documents

Publication Publication Date Title
AU2022201204B2 (en) Stabilization of Fc-containing polypeptides
JP6329585B2 (ja) 単量体抗体Ｆｃ
CN110234355B (zh) 单体人IgG1 Fc和双特异性抗体
JP2019519527A (ja) 操作されたＦｃコンストラクトに関する組成物及び方法
KR20230025673A (ko) CD3 및 FolR1에 결합하는 항체
WO2015035215A1 (en) Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
JP2025128211A (ja) ヒト化抗ｉｌ－１ｒ３抗体及び使用方法
JP7792044B2 (ja) ヒト化抗ｉｌ－１ｒ３抗体及び使用方法

Legal Events

Date Code Title Description
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501